They identified 1,415 differentially methylated sites in the promoter regions of T2D subjects compared to normoglycaemic controls, of which over 80% were hypermethylated, including the following genes: B-Cell CLL/Lymphoma 3 (BCL3), Interleukin 23 Subunit Alpha (IL23A), F2R Like Trypsin Receptor 1 (F2RL1), S100 Calcium Binding Protein A12 (S100A12), TNF Receptor Superfamily Member 10b (TNFRSF10B), NIMA Related Kinase 6 (NEK6), Ring Finger Protein 31 (RNF31), Solute Carrier Family 35 Member B2 (SLC35B2), and Interleukin 1 Receptor Associated Kinase 1 Binding Protein 1 (IRAK1BP1). The gene discussed is SLC35B2; the disease is B-cell chronic lymphocytic leukemia.